Robert (Bob) Ward is President and Chief Executive Officer of Radius. He is a global pharmaceutical industry leader managing all stages of drug development, commercialization, and strategic dealmaking and partnerships across multiple therapeutic areas. Prior to joining Radius, Mr. Ward was Vice President for Strategy and External Alliances for the New Opportunities iMed of AstraZeneca (AZ), where he led search and evaluate activities in areas outside of AZ’s historical therapeutic focus, including orphan drugs and endocrinology. In addition, he served as Co-Chair of the Joint Development Committees in AZ’s drug development partnerships with Alcon and Galderma. After starting his career in the Molecular Biology discovery group at Genentech, Mr. Ward progressed through a series of management and executive roles with established biopharmaceutical companies including NPS Pharmaceuticals, Schering-Plough (Merck), and Bristol-Myers Squibb. Mr. Ward received a B.A. in Biology and a B.S. in Physiological Psychology, both from the University of California, Santa Barbara; an M.S. in Management from the New Jersey Institute of Technology; and an M.A. in Immunology from The Johns Hopkins University School of Medicine.
Nick Harvey is Senior Vice President and Chief Financial Officer of Radius. He has more than 15 years of experience in building and financing life sciences and technology companies. Prior to joining Radius, he served for four years as Managing Director of Shiprock Capital, a venture capital firm, where he was responsible for deal-sourcing, negotiating and closing transactions, and developing strategic plans for portfolio companies. Before that, Mr. Harvey served as CFO of a number of venture-backed companies over a 10-year period, including Transfusion Technologies and Transcend Therapeutics. At Transfusion, he helped to close a major distribution agreement with Zimmer and oversaw the company's acquisition by Haemonetics. Mr. Harvey holds an undergraduate degree in Economics and a law degree with first-class honors from the Australian National University, and an MBA from the Harvard Business School.
Dr. Yates is Chief Medical Officer of Radius. He has over 30 years of experience in clinical science and pharmaceutical drug development. Prior to joining Radius, Dr. Yates served as President of Global Research and Development for Takeda Pharmaceuticals, where he led the successful new drug application filings of two new chemical entities and strengthened the development pipeline across multiple therapeutic areas. Prior to that, Dr. Yates served in a number of positions at Merck over a 14-year period. During that time, he led the development of the osteoporosis drug Fosamax® (alendronate). Dr. Yates received M.B., Ch.B. and M.D. degrees from Sheffield University Medical School, in Sheffield, UK. He gained further experience in academic medical research at the University of Melbourne, Australia and the University of Texas Health Science Center in San Antonio where his contributions included the early characterization of a PTH-related protein—the naturally occurring peptide upon which Radius’ lead compound is based. Dr. Harris is Executive Medical Officer of Radius. He has over 25 years of experience in clinical research and development. Dr. Harris carries expertise in endocrinology, metabolism, diabetes, oncology, gastroenterology, cardiovascular disease, allergic and respiratory diseases. He has played a central role in the approval process and clinical development of 17 peptides, small molecules, and biological pharmaceutical drugs, including Natpara® (rhPTH 1-84), and has conducted or overseen hundreds of clinical trials in over 30 countries. Dr. Harris is the founder and chairman of Sompharmaceuticals SA, a Swiss company focused on the discovery and development of new generation of somatostatin peptide analogues for the treatment of Growth Hormone producing brain tumors that cause acromegaly and malignant Neuroendocrine Tumors (NETs) including carcinoids. Dr. Harris earned his medical degree from the Louis Pasteur Faculty of Medicine, University of Strasbourg, France, and his Ph.D. in endocrinology from Erasmus University, Rotterdam, The Netherlands. Dr. Williams is Chief Development Officer of Radius. He is a pharmaceutical industry and drug development veteran with more than 30 years of experience leading new product development, regulatory affairs, lifecycle management and commercialization for both small biotechnology and large pharmaceutical companies. Prior to joining Radius, Dr. Williams was Vice President of Regulatory Affairs, Global Product and Clinical Development, and Program Management with The Medicines Company, where he led the successful NDA and MAA filings of the IV antihypertensive drug Cleviprex®. Earlier positions include Vice President of Regulatory Affairs, Regulatory Compliance and Program Management for NPS Pharmaceuticals, where he led the successful MAA filing of the osteoporosis drug Preotact™. He has also held various management positions in clinical and drug product development for Yamanouchi Pharma America, Theraport Biosciences, GlaxoSmithKline Consumer Healthcare, and Parke-Davis Pharmaceutical. Dr. Williams has a Ph.D. in Biopharmaceutics from Rutgers University and an MBA from Cornell University. Dr. Hattersley is Chief Scientific Officer of Radius. He has more than 20 years of experience in musculoskeletal research and is the author of numerous scientific publications related to bone biology and physiology. Prior to joining Radius, Dr. Hattersley was a Senior Scientist at Millennium Pharmaceuticals with responsibility for the discovery and development of novel small-molecule agents for the treatment of osteoporosis and other metabolic bone diseases. Dr. Hattersley also held positions at Genetics Institute/Wyeth Research investigating the application of the bone morphogenetic proteins in bone and connective tissue repair and regeneration. Dr. Hattersley received a PhD in Experimental Pathology from St. George's Hospital Medical School in London.